|
 
- 现金
- 20661 元
- 精华
- 7
- 帖子
- 12793
- 注册时间
- 2013-12-29
- 最后登录
- 2024-11-3
|
结论 • The combination of ABI-H0731 + NrtI demonstrated faster and
greater reductions in viral nucleic acid levels than NrtI therapy alone,
with “DNA TND” and “pgRNA <35 U/mL” thresholds only being
achieved in patients receiving ABI-H0731 + NrtI
• Long-term treatment with ABI-H0731 + NrtI results in continued
deep reductions in HBV DNA and pgRNA as measured by high
sensitivity PCR assays
• Second phase declines in pgRNA (>3 logs), a primary surrogate
marker of cccDNA, were strongly associated with reductions in viral
antigens, suggesting declining cccDNA pools
• ABI-H0731 is well-tolerated when chronically administered in
combination with NrtI and no serious adverse events have been
reported to date
• Treatment-emergent adverse events and laboratory abnormalities
associated with ABI-H0731 + NrtI were generally Grade 1 or Grade 2
in severity and resolved without treatment interruption |
|
发表于 2020-5-13 23:08
